{"id":"NCT01165177","sponsor":"GlaxoSmithKline","briefTitle":"Study to Evaluate Efficacy, Safety and Immunogenicity of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 50 Years and Older","officialTitle":"Efficacy, Safety, and Immunogenicity Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults Aged 50 Years or Older","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-08-02","primaryCompletion":"2014-05-09","completion":"2015-07-27","firstPosted":"2010-07-19","resultsPosted":"2017-05-01","lastUpdate":"2021-02-10"},"enrollment":16165,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"PREVENTION"},"conditions":["Herpes Zoster"],"interventions":[{"type":"BIOLOGICAL","name":"Herpes Zoster Vaccine GSK1437173A","otherNames":[]},{"type":"BIOLOGICAL","name":"Placebo","otherNames":[]}],"arms":[{"label":"GSK1437173A group","type":"EXPERIMENTAL"},{"label":"Placebo group","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this observer-blind study is to evaluate the efficacy, safety and immunogenicity of GSK Biologicals' candidate Herpes Zoster (HZ) vaccine in adults aged â‰¥ 50 years.\n\nTwo studies \\[ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229)\\] are being conducted concurrently to evaluate efficacy of GSK1437173A vaccine. A pooled analysis of data from both studies combined will be conducted contingent on each study achieving its objectives. The protocol posting of study ZOSTER-022 also deals with the outcome measures related to the pooled analysis.","primaryOutcome":{"measure":"Number of Subjects With Confirmed Herpes Zoster (HZ) Cases","timeFrame":"During the entire study period (3 to 5 year period following Day 0)","effectByArm":[{"arm":"GSK1437173A 50-59 YOA Group","deltaMin":3,"sd":null},{"arm":"GSK1437173A 60-69 YOA Group","deltaMin":2,"sd":null},{"arm":"GSK1437173A Over 70 YOA Group","deltaMin":1,"sd":null},{"arm":"GSK1437173A Overall Ages Group","deltaMin":6,"sd":null},{"arm":"Placebo 50-59 YOA Group","deltaMin":87,"sd":null},{"arm":"Placebo 60-69 YOA Group","deltaMin":75,"sd":null},{"arm":"Placebo Over 70 YOA Group","deltaMin":48,"sd":null},{"arm":"Placebo Overall Ages Group","deltaMin":210,"sd":null}],"pValues":[{"comp":"OG000 vs OG004","p":"<0.0001"},{"comp":"OG001 vs OG005","p":"<0.0001"},{"comp":"OG002 vs OG006","p":"0.0001"},{"comp":"OG003 vs OG007","p":"<0.0001"}]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":4,"exclusionCount":14},"locations":{"siteCount":274,"countries":["United States","Australia","Brazil","Canada","Czechia","Estonia","Finland","France","Germany","Hong Kong","Italy","Japan","Mexico","South Korea","Spain","Sweden","Taiwan","United Kingdom"]},"refs":{"pmids":["27626517","29529222","29463421","25916341","37166199","36066965","34609490","33606577","32910152","32347767","31537443","30935742","29955836"],"seeAlso":["https://clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":727,"n":7695},"commonTop":["Pain","Headache","Fatigue","Myalgia","Erythema"]}}